CYP19A1 and neoplasm: In the case of breast cancer, it acts both as a selective estrogen receptor modulator (like tamoxifen) and as a selective enzyme receptor modulator (like aromatase inhibitors) [56] in order to decrease the influx of estrogens in the tumor cell [57].